• 1
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996; 23: 164176.
  • 2
    Gines A, Escorsell, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis and ascites. Gastroenterology 1993; 105: 229236.
  • 3
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, et al. Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 1973; 289: 11551159.
  • 4
    Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 16581676.
  • 5
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923930.
  • 6
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin J-L, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002; 36: 374380.
  • 7
    Angeli P, Volpin R, Gerunda G, Craighero R, Merenda R, Bottaro S, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999; 29: 16901697.
  • 8
    Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. HEPATOLOGY 2003; 38: 238243.
  • 9
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288295.
  • 10
    Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intra-hepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. HEPATOLOGY 1998; 28: 416422.
  • 11
    Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis LM. The effects of transjugular intrahepatic portasystemic shunt on systemic and renal hemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. Ann Intern Med 1995; 122: 816822.
  • 12
    Wong F, Sniderman K, Liu P, Blendis LM. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 112: 899907.
  • 13
    Wong W, Liu P, Blendis LM, Wong F. Renal sodium handling during long-term follow-up and the effect of sodium loading in cirrhotic patients treated with TIPS for refractory ascites. Am J Med 1999; 106: 315322.
  • 14
    Wong F, Liu P, Blendis LM. The mechanism of improved sodium homeostasis of low-dose losartan in pre-ascitic cirrhosis. HEPATOLOGY 2002; 35: 14491458.
  • 15
    Wong F, Liu P, Tobe S, Morali G, Blendis LM. Central blood volume in cirrhosis: measurement by radionuclide angiography. HEPATOLOGY 1994; 19: 312321.
  • 16
    Wong F, Blendis LM. Transjugular intrahepatic portasystemic shunt-Tipping the sodium balance. HEPATOLOGY 1995; 22: 358364.
  • 17
    Morali GA, Sniderman KW, Deitel KM, Witt-Sullivan H, Simon M, Heathcote J, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J HEPATOLOGY 1992; 16: 249250.
  • 18
    Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley K, Benner K, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003: 124: 634643.
  • 19
    Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath P, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 18391847.
  • 20
    Eriksson BM, Persson BA. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr 1982; 228: 143152.
  • 21
    Weicker H, Feraudi M, Hagele H, Pluto R. Electrochemical detection of catecholamines in urine and plasma after separation with HPLC. Clin Chim Acta 1984; 4: 1725.
  • 22
    Walser M, Davidson DG, Orloff J. The renal clearance of alkali-stable inulin. J Clin Invest 1955; 34: 15201523.
  • 23
    Brun C. A rapid method for the determination of para-aminohippuric acid in kidney function tests. J Lab Clin Med 1951; 37: 955958.
  • 24
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1998; 8: 11511157.
  • 25
    Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993; 105: 11671172.
  • 26
    Barriere E, Tazi KA, Pessione F, Heller J, Poirel O, Lebrec D, et al. Role of small-conductance Ca2+-dependent K+ channels in in-vitro nitric oxide-mediated aortic hyporeactivity to alpha-adrenergic vasoconstriction in rats with cirrhosis. J Hepatol 2001; 35: 350357.
  • 27
    MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. HEPATOLOGY 1991; 13: 689694.
  • 28
    Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. HEPATOLOGY 1993; 18: 367372.
  • 29
    Arkenau HT, Stichtenoth DO, Frolich JC, Manns MP, Boker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 2002; 40: 907913.
  • 30
    Braillon A, Cales P, Valla D, Gandy D, Geoffrey P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic hemodymics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 12041209.
  • 31
    Dagher L, Patch D, Marley R, Moore K, Burrough A. Review article: pharmacological treatment of hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000; 14: 515521.
  • 32
    Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277286.
  • 33
    Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 16371648.
  • 34
    Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664670.
  • 35
    Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome—experience in 300 patients. Transplantation 1991; 51: 428430.
  • 36
    Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pre-transplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159164.
  • 37
    Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140146.